The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...
Bristol Myers Squibb is buying startup Orbital Therapeutics for $1.5 billion, aiming to develop more scalable cell therapies ...
Bristol Myers Squibb (BMS) has announced the acquisition of Orbital Therapeutics, a privately held biotech specializing in ...
Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...
Axi-cel demonstrated superior progression-free survival compared to tisa-cel, despite a higher toxicity profile, including increased neurotoxicity and cytokine release syndrome. The CAR-HEMATOTOX ...
Looking to build a new laboratory or expand your existing facility. Talk to your Formaspace Design Consultant about our custom lab furniture solutions, built in the USA, at our Austin, Texas, factory ...
BCMA-targeting CAR T-cell therapy shows similar efficacy and safety for REMPs and non-REMPs, despite access disparities. REMPs experience reduced access to CAR T therapy, with significant drops in ...
Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback